Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05, Briefing.com reports. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The company had revenue of […]

Definitive Healthcare (NASDAQ:DH – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided EPS guidance of 0.340-0.350 for the period, compared to the consensus EPS estimate of 0.330. The company issued revenue guidance of $250.0 million-$251.0 million, compared to the consensus revenue estimate of $249.2 million. Definitive Healthcare also updated […]

RingCentral (NYSE:RNG – Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 0.960-0.970 for the period, compared to the consensus EPS estimate of 0.950. The company issued revenue guidance of $611.0 million-$613.0 million, compared to the consensus revenue estimate of $616.0 million. […]

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.06, Briefing.com reports. The business had revenue of $250.40 million during the quarter, compared to the consensus estimate of $248.83 million. ACADIA […]

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.07, Briefing.com reports. The company had revenue of $250.40 million during the quarter, compared to analyst estimates of $248.83 million. ACADIA Pharmaceuticals had […]

Definitive Healthcare (NASDAQ:DH – Get Free Report) issued an update on its fourth quarter earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.07 for the period, compared to the consensus estimate of $0.06. The company issued revenue guidance of $60-$61 million, compared to the consensus revenue estimate of $60.33 […]